The latest updates you cannot miss.
Edition 2 | 2025
Important achievements for our high energy cyclotron, Cyclone® IKON
Over the past few months, we have achieved significant milestones with our high energy cyclotron, Cyclone® IKON, reflecting the dedication of our team and, most importantly, the invaluable close collaboration with our users.
From delivery to installation, a remarkable journey began at Institute for RadioElements (IRE) in Belgium where their Cyclone® IKON was successfully rigged.
On its North American headquarters and historical St. Louis site, Curium started the operations with their Cyclone® IKON, CE marked. Thereby, they are securing a reliable large-scale production of novel radioisotopes.
The story doesn't end there. Building on these successes, we are already writing new chapters with, among others, the signature of a contract between IBA and PET Pharm Bio for the installation of a new high energy cyclotron in Taiwan.
CASSY® launched at iSRS!
After months of development, we successfully launched CASSY®, our Compact Automated Scalable Synthesis module, at iSRS!
This new radiochemistry module enhances efficiency in radiopharmaceuticals production, especially radiometals.
CASSY® | Compact Automated Scalable Synthesis
Successful rigging of the 100th Cyclone® KIUBE
This rigging holds a special place in our heart as it marks our 100th release of Cyclone® KIUBE at Herlev Hospital, a long-standing user, in Denmark!
Since its inception, it has been a real game changer on the cyclotron market thanks to its compact design. Its high performance capacity enables our customers to produce a large range of PET radioisotopes including 18F, 68Ga, 89Zr, 11C and many others used in oncology, cardiology and neurology imaging.
First pilot study for our IHI project, Accelerate.EU
Accelerate.EU, coordinated by IBA and Jules Bordet Institute, will launch its first pilot study with Astatine-211 [211At] in 2026. The randomised [211At] At-Substance P clinical trial for the treatment of recurrent glioblastoma (GBM) will take place in Coimbra (Portugal). Preclinical studies are underway this year, involving several members of the consortium, ICNAS (Portugal), Tetrakit (Denmark), Arronax (France) and Jules Bordet Institute (Belgium).
First milestone for Framatome and IBA partnership
Framatome selected the location for the dedicated production pilot facility at Saint-Herblain, France, close to Arronax Nantes.
It is the first milestone for the strategic partnership between Framatome and IBA, aimed to build a global and reliable industrial network for the timely production of Astatine-211 compounds in the USA and Europe.
On-demand Webinar available
Innovations & Future Outlook in Radiotheranostics
Prof M. Ghesani & Prof C. Deroose shared their insights on the latest advancements in radiotheranostics in United States and Europe.
Inspiring SNMMI congress!
Thank you to all participants to this year's SNMMI congress at New Orleans, US.
During this edition, we had the opportunity to show our latest innovations.
- Elevate your radiochemistry with CASSY®
- Achieve more with less thanks to our Nirta® HeFree Target
- Unlock your full potential on Cyclone® KIUBE with our IBA Kare Portal
- Discover IntegraLab®, the integrated radiopharmacy solution tailored to your needs
 |
 |